PREMARIN (estrogens, conjugated)
ATROPHY OF VULVA·+2
WYETH PHARM
Indication
Dyspareunia due to menopause-associated vulvovaginal atrophy
Dyspareunia due to menopause-associated vulvovaginal atrophy is a sexual pain disorder affecting the female reproductive system in perimenopausal and postmenopausal individuals. Read more about Dyspareunia due to menopause-associated vulvovaginal atrophy
15 drugs 10 manufacturers
Drugs that treat it
Common Dyspareunia due to menopause-associated vulvovaginal atrophy therapies.
OSPHENA (ospemifene)
ATROPHIC VAGINITIS ASSOCIATED WITH MENOPAUSE·+1
SHIONOGI PHARMA
PREMARIN (estrogens, conjugated)
ESTROGENS·ATROPHY OF VULVA·+2
Wyeth Pharmaceutical
INTRAROSA (prasterone (DHEA))
DYSPAREUNIA DUE TO MENOPAUSE-ASSOCIATED VULVOVAGINAL ATROPHY
AMAG PHARMACEUT
IMVEXXY (estradiol)
DYSPAREUNIA DUE TO MENOPAUSE-ASSOCIATED VULVOVAGINAL ATROPHY
THERAPEUTICSMD
IMVEXXY (estradiol)
DYSPAREUNIA DUE TO MENOPAUSE-ASSOCIATED VULVOVAGINAL ATROPHY
THERAPEUTICSMD
INTRAROSA (prasterone (DHEA))
VAGINAL ESTROGENS·DYSPAREUNIA DUE TO MENOPAUSE-ASSOCIATED VULVOVAGINAL ATROPHY
MILLICENT PHARM
INTRAROSA (prasterone (DHEA))
DYSPAREUNIA DUE TO MENOPAUSE-ASSOCIATED VULVOVAGINAL ATROPHY
AMAG/COVIS PHAR
OSPHENA (ospemifene)
ANTIESTROGEN·ATROPHIC VAGINITIS ASSOCIATED WITH MENOPAUSE·+1
DUCHESNAY USA,
Filter & compare in the drug finder →Opens the drug finder with Dyspareunia due to menopause-associated vulvovaginal atrophy preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonDyspareunia due to menopause-associated vulvovaginal atrophy is a sexual pain disorder affecting the female reproductive system in perimenopausal and postmenopausal individuals.
It is characterized by persistent or recurrent pain, burning, or discomfort during sexual intercourse, resulting directly from the hypoestrogenic state of natural or surgical menopause.
Pathophysiologically, the decline in circulating estrogens leads to thinning and loss of elasticity in the vaginal epithelium, decreased mucosal lubrication, loss of rugae, and an elevation in vaginal pH.
These structural changes leave the vulvar and vaginal tissues fragile, dry, and prone to friction-induced irritation and microtrauma during penetration.
- pharmacytimes.com
Dyspareunia due to menopause-associated vulvovaginal atrophy is a sexual pain disorder affecting the female reproductive system in perimenopausal and postmenopausal individuals It is characterized by persistent or recurrent pain, burning, or discomfort during sexual intercourse, resulting directly from the hypoestrogenic state of natural or surgical menopause
- nih.gov
Dyspareunia due to menopause-associated vulvovaginal atrophy is a sexual pain disorder affecting the female reproductive system in perimenopausal and postmenopausal individuals
- nih.gov
It is characterized by persistent or recurrent pain, burning, or discomfort during sexual intercourse, resulting directly from the hypoestrogenic state of natural or surgical menopause
- nih.gov
It is characterized by persistent or recurrent pain, burning, or discomfort during sexual intercourse, resulting directly from the hypoestrogenic state of natural or surgical menopause These structural changes leave the vulvar and vaginal tissues fragile, dry, and prone to friction-induced irritation and microtrauma during penetration
- nih.gov
Pathophysiologically, the decline in circulating estrogens leads to thinning and loss of elasticity in the vaginal epithelium, decreased mucosal lubrication, loss of rugae, and an elevation in vaginal pH These structural changes leave the vulvar and vaginal tissues fragile, dry, and prone to friction-induced irritation and microtrauma during penetration
Personalize your experience
Follow Dyspareunia due to menopause-associated vulvovaginal atrophy and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.